Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles

Nanomedicine

Volumn 7, Issue 5, 2012, Pages 679-690

  Estella Hermoso De Mendoza, Ander ^a   Campanero, Miguel A ^b   Lana, Hugo ^a   Villa Pulgarin, Janny A ^c   De La Iglesia Vicente, Janis ^c   Mollinedo, Faustino ^c   Blanco Prieto, María J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

bioavailability; biodistribution; edelfosine; lipid nanoparticles; lymphoma; pharmacokinetic

Indexed keywords

EDELFOSINE; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SOLUTION; HEMOLYSIS; LYMPH NODE; LYMPHOMA; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; DIGLYCERIDES; FATTY ACIDS; HUMANS; LEUKEMIC INFILTRATION; LYMPH NODES; LYMPHOMA; MICE; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; PHOSPHOLIPID ETHERS;

EID: 84861623217     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.134     Document Type: Article

References (48)

1. Gajate C, Mollinedo F. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH3 (edelfosine), a proapoptotic agent in tumor cells. Curr. Drug. Metab. 3(5), 491-525 (2002). (Pubitemid 34987482)
2. Estella-Hermoso De Mendoza A, Campanero MA, De La Iglesia-Vicente J, Gajate C, Mollinedo F, Blanco-Prieto MJ. Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin. Cancer Res. 15(3), 858-864 (2009).
3. Ahmad I, Filep JJ, Franklin JC et al. Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Cancer Res. 57(10), 1915-1921 (1997). (Pubitemid 27209721)
4. Houlihan WJ, Lohmeyer M, Workman P, Cheon SH. Phospholipid antitumor agents. Med. Res. Rev. 15(3), 157-223 (1995).
5. Munder PG, Westphal O. Antitumoral and other biomedical activities of synthetic ether lysophospholipids. Chem. Immunol. 49, 206-235 (1990).
6. Bhamra R, Bolcsak Le, Ahmad I et al. Activity, pharmacokinetics and tissue distribution of TLC ELL-12 (liposomal antitumor ether lipid) in rats with transplantable, s.c. methylnitrosourea-induced tumors. Anticancer Drugs 14(6), 481-486 (2003). (Pubitemid 36951801)
7. Estella-Hermoso De Mendoza A, Rayo M, Mollinedo F, Blanco-Prieto MJ. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: development and in vitro characterization. Eur. J. Pharm. Biopharm. 68(2), 207-213 (2008).
8. Estella-Hermoso De Mendoza A, Campanero MA, Mollinedo F, Blanco-Prieto MJ. Lipid nanomedicines for anticancer drug therapy. J. Biomed. Nanotechnol. 5, 1-21 (2009).
9. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47(2-3), 165-196 (2001). (Pubitemid 32324113)
10. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf. B Biointerfaces 45 (3-4), 167-173 (2005). (Pubitemid 41415646)
11. Siekmann B, Westesen K. Sub-micron sized parenteral carrier systems based on solid lipids. Pharm. Pharmacol. Lett. 1, 123 (1992).
12. Cavalli R, Caputo O, Carlotti Me, Trotta M, Scarnecchia C, Gasco MR. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int. J. Pharm. 148, 47-54 (1997). (Pubitemid 27152216)
13. Chen DB, Yang TZ, Lu WL, Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull. 49(11), 1444-1447 (2001). (Pubitemid 33043274)
14. Bertoni F, Rinaldi A, Zucca E, Cavalli F. Update on the molecular biology of mantle cell lymphoma. Hematol. Oncol. 24(1), 22-27 (2006).
15. Andersen NS, Pedersen LB, Laurell A et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J. Clin. Oncol. 27(26), 4365-4370 (2009).
16. Diefenbach CS, O'Connor OA. Mantle cell lymphoma in relapse: the role of emerging new drugs. Curr. Opin. Oncol. 22(5), 419-423 (2010).
17. Dreger P, Rieger M, Seyfarth B et al. Rituximab-augmented myeloablation for frst-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 92(1), 42-49 (2007). (Pubitemid 46237555)
18. Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Current management of mantle cell lymphoma. Drugs 67(12), 1689-1702 (2007). (Pubitemid 47263445)
19. Williams ME, Densmore JJ. Biology and therapy of mantle cell lymphoma. Curr. Opin. Oncol. 17(5), 425-431 (2005). (Pubitemid 41226481)
20. Park Bb, Kim Ws, Eom Hs et al. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial. Invest. New Drugs 29(1), 154-160 (2011).
21. Clogston JD, Patri AK. Zeta potential measurement. Methods Mol. Biol. 697, 63-70 (2011).
22. Kaszuba M, Corbett J, Watson FM, Jones A. High-concentration zeta potential measurements using light-scattering techniques. Philos. Transact. A Math Phys. Eng. Sci. 368(1927), 4439-4451 (2010).
23. Estella-Hermoso De Mendoza A, Campanero MA, Mollinedo F, Blanco-Príeto MJ. Comparative study of a HPLC-MS assay versus an UHPLC-MS/MS for anti-tumoral alkyl lysophospholipid edelfosine determination in both biological samples and in lipid nanoparticulate systems. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 4035-4041 (2009).
24. Charman WN, Stella VJ. Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules. Int. J. Pharm. 34, 175-178 (1986).
25. Shah M, Chuttani K, Mishra Ak, Pathak K. Oral solid compritol 888 ATO nanosuspension of simvastatin: optimization and biodistribution studies. Drug Dev. Ind. Pharm. 37(5), 526-537 (2011).
26. Varshosaz J, Minayian M, Moazen E. Enhancement of oral bioavailability of pentoxifylline by solid lipid nanoparticles. J. Liposome Res. 20(2), 115-123 (2010).
27. Paliwal R, Rai S, Vaidya B et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 5(2), 184-191 (2009).
28. Levy My, Schutze W, Fuhrer C, Benita S. Characterization of diazepam submicron emulsion interface: role of oleic acid. J. Microencapsul. 11(1), 79-92 (1994). (Pubitemid 24030965)
29. Teeranachaideekul V, Muller RH, Junyaprasert VB. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)-effects of formulation parameters on physicochemical stability. Int. J. Pharm. 340(1-2), 198-206 (2007). (Pubitemid 47049784)
30. Hou D, Xie C, Huang K, Zhu C. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 24(10), 1781-1785 (2003). (Pubitemid 36184733)
31. Kotting J, Marschner Nw, Neumuller W, Unger C, Eibl H. Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of hemolytic activity, serum binding and tissue distribution. Prog. Exp. Tumor Res. 34, 131-142 (1992).
32. Aji Alex MR, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci. 42(1-2), 11-18 (2011).
33. Constantinides PP, Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J. Pharm. Sci. 96(2), 235-248 (2007). (Pubitemid 46363554)
34. Rege BD, Kao JP, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 16(4-5), 237-246 (2002).
35. Hu L, Jia H, Luo Z, Liu C, Xing Q. Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles. Pharmazie 65(2), 110-113 (2010).
36. Hu L, Xing Q, Meng J, Shang C. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS Pharm Sci Tech. 11(2), 582-587 (2010).
37. Tsai MJ, Huang YB, Wu PC et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifers: pharmacokinetic and behavioral evaluations. J. Pharm. Sci. 100(2), 547-557 (2011).
38. Rawat MK, Jain A, Singh S. In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats. J. Pharm. Sci. 100(6), 2406-2417 (2011).
39. Kreuter J. Peroral administration of nanoparticles. Adv. Drug Deliv. Rev. 7(1), 71-86 (1991).
40. Florence AT, Hillery AM, Hussain N, Jani PU. Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. J. Drug Target. 3(1), 65-70 (1995).
41. Caliph SM, Charman WN, Porter CJ. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J. Pharm. Sci. 89(8), 1073-1084 (2000).
42. Varma MV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol. Res. 48(4), 347-359 (2003). (Pubitemid 36945333)
43. Bargoni A, Cavalli R, Caputo O, Fundaro A, Gasco MR, Zara GP. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm. Res. 15(5), 745-750 (1998). (Pubitemid 28275652)
44. Mollinedo F, De La Iglesia-Vicente J, Gajate C et al. In vitro and in vivo selective antitumor activity of edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin. Cancer Res. 16(7), 2046-2054 (2010).
45. Brody J, Advani R. Treatment of mantle cell lymphoma: current approach and future directions. Crit. Rev. Oncol. Hematol. 58(3), 257-265 (2006). (Pubitemid 44425194)
46. Lu B, Xiong SB, Yang H, Yin XD, Chao RB. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur. J. Pharm. Sci. 28(1-2), 86-95 (2006).
47. Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Mantle cell lymphoma: state-of-the-art management and future perspective. Leuk. Lymphoma 50(12), 1937-1950 (2009).
48. Ogura M. Current treatment strategy and new agents in mantle cell lymphoma. Int. J. Hematol. 92(1), 25-32 (2010).